ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Taxotere Encouraging, CPT-11, Other Agents Entering Trials; Chabner

July 10, 1992

NIH Panel Outlines Strategies To Manage Adrenal Tumors.

February 22, 2002

NCI Reportedly Gets $691 Million From House, Senate Conferees

October 4, 1974

Mortality, Survival Still Improving for Whites, Remain Static Or Decline For Blacks; Largest Survival Increase For Whites In history Of SEER Program

June 2, 1989

In Brief: House Fills Subcommittee Positions; Senate Schedules NCI Appropriations Hearing Feb. 18

February 13, 1981

Senate approves NIH funding bill. NCI awards $25 million to eight institutions for patient navigator programs; $35 million awarded for nanotechnology partnerships.

October 28, 2005